# Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

> **NCT05260671** · PHASE2 · RECRUITING · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 48 (estimated)

## Conditions studied

- Head and Neck Neoplasms
- Recurrent Disease
- Metastatic Cancer

## Interventions

- **DRUG:** Penpulimab combined with cetuximab

## Key facts

- **NCT ID:** NCT05260671
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-25
- **Primary completion:** 2024-12-25
- **Final completion:** 2026-12-25
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05260671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05260671, "Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05260671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*